vs
Amphastar Pharmaceuticals, Inc.（AMPH）与WSFS FINANCIAL CORP（WSFS）财务数据对比。点击上方公司名可切换其他公司
WSFS FINANCIAL CORP的季度营收约是Amphastar Pharmaceuticals, Inc.的1.5倍（$275.3M vs $183.1M），WSFS FINANCIAL CORP净利率更高（31.5% vs 13.3%，领先18.2%），WSFS FINANCIAL CORP同比增速更快（7.5% vs -1.8%），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs 1.7%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
WSFS金融集团是一家金融服务企业，核心子公司WSFS银行是总部位于特拉华州及大特拉华谷地区规模最大、经营历史最久的本地管理银行与财富管理机构。集团共运营115个网点，其中88个为银行网点，分布在宾夕法尼亚、特拉华、新泽西、佛罗里达、弗吉尼亚、内华达六州，提供全面金融服务。
AMPH vs WSFS — 直观对比
营收规模更大
WSFS
是对方的1.5倍
$183.1M
营收增速更快
WSFS
高出9.3%
-1.8%
净利率更高
WSFS
高出18.2%
13.3%
两年增速更快
AMPH
近两年复合增速
1.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $275.3M |
| 净利润 | $24.4M | $86.8M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 19.4% | — |
| 净利率 | 13.3% | 31.5% |
| 营收同比 | -1.8% | 7.5% |
| 净利润同比 | -35.7% | 31.7% |
| 每股收益（稀释后） | $0.51 | $1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHWSFS
| Q1 26 | — | $275.3M | ||
| Q4 25 | $183.1M | $271.9M | ||
| Q3 25 | $191.8M | $270.5M | ||
| Q2 25 | $174.4M | $267.5M | ||
| Q1 25 | $170.5M | $256.1M | ||
| Q4 24 | $186.5M | $261.5M | ||
| Q3 24 | $191.2M | $267.7M | ||
| Q2 24 | $182.4M | $266.0M |
净利润AMPHWSFS
| Q1 26 | — | $86.8M | ||
| Q4 25 | $24.4M | $72.7M | ||
| Q3 25 | $17.4M | $76.4M | ||
| Q2 25 | $31.0M | $72.3M | ||
| Q1 25 | $25.3M | $65.9M | ||
| Q4 24 | $38.0M | $64.2M | ||
| Q3 24 | $40.4M | $64.4M | ||
| Q2 24 | $37.9M | $69.3M |
毛利率AMPHWSFS
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
营业利润率AMPHWSFS
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | 35.8% | ||
| Q3 25 | 13.2% | 37.3% | ||
| Q2 25 | 24.2% | 35.7% | ||
| Q1 25 | 21.9% | 34.0% | ||
| Q4 24 | 24.2% | 32.3% | ||
| Q3 24 | 29.8% | 31.9% | ||
| Q2 24 | 30.3% | 34.0% |
净利率AMPHWSFS
| Q1 26 | — | 31.5% | ||
| Q4 25 | 13.3% | 26.7% | ||
| Q3 25 | 9.0% | 28.3% | ||
| Q2 25 | 17.8% | 27.0% | ||
| Q1 25 | 14.8% | 25.7% | ||
| Q4 24 | 20.4% | 24.6% | ||
| Q3 24 | 21.1% | 24.1% | ||
| Q2 24 | 20.8% | 26.0% |
每股收益（稀释后）AMPHWSFS
| Q1 26 | — | $1.64 | ||
| Q4 25 | $0.51 | $1.33 | ||
| Q3 25 | $0.37 | $1.37 | ||
| Q2 25 | $0.64 | $1.27 | ||
| Q1 25 | $0.51 | $1.12 | ||
| Q4 24 | $0.74 | $1.08 | ||
| Q3 24 | $0.78 | $1.08 | ||
| Q2 24 | $0.73 | $1.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | — |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $2.7B |
| 总资产 | $1.6B | $22.1B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHWSFS
| Q1 26 | — | — | ||
| Q4 25 | $282.8M | $1.7B | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | $1.2B | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — |
总债务AMPHWSFS
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
股东权益AMPHWSFS
| Q1 26 | — | $2.7B | ||
| Q4 25 | $788.8M | $2.7B | ||
| Q3 25 | $776.7M | $2.8B | ||
| Q2 25 | $757.5M | $2.7B | ||
| Q1 25 | $751.3M | $2.7B | ||
| Q4 24 | $732.3M | $2.6B | ||
| Q3 24 | $727.7M | $2.7B | ||
| Q2 24 | $713.3M | $2.5B |
总资产AMPHWSFS
| Q1 26 | — | $22.1B | ||
| Q4 25 | $1.6B | $21.3B | ||
| Q3 25 | $1.7B | $20.8B | ||
| Q2 25 | $1.6B | $20.8B | ||
| Q1 25 | $1.6B | $20.5B | ||
| Q4 24 | $1.6B | $20.8B | ||
| Q3 24 | $1.5B | $20.9B | ||
| Q2 24 | $1.5B | $20.7B |
负债/权益比AMPHWSFS
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | — |
| 自由现金流经营现金流 - 资本支出 | $24.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | — |
8季度趋势，按日历期对齐
经营现金流AMPHWSFS
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $220.0M | ||
| Q3 25 | $52.6M | $121.5M | ||
| Q2 25 | $35.6M | $37.2M | ||
| Q1 25 | $35.1M | $8.7M | ||
| Q4 24 | $29.0M | $219.9M | ||
| Q3 24 | $60.0M | $3.1M | ||
| Q2 24 | $69.1M | $44.8M |
自由现金流AMPHWSFS
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $213.6M | ||
| Q3 25 | $47.2M | $120.3M | ||
| Q2 25 | $25.0M | $35.2M | ||
| Q1 25 | $24.4M | $6.3M | ||
| Q4 24 | $16.6M | $205.6M | ||
| Q3 24 | $46.2M | $-489.0K | ||
| Q2 24 | $63.1M | $42.1M |
自由现金流率AMPHWSFS
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 78.6% | ||
| Q3 25 | 24.6% | 44.5% | ||
| Q2 25 | 14.3% | 13.2% | ||
| Q1 25 | 14.3% | 2.5% | ||
| Q4 24 | 8.9% | 78.6% | ||
| Q3 24 | 24.1% | -0.2% | ||
| Q2 24 | 34.6% | 15.8% |
资本支出强度AMPHWSFS
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 2.3% | ||
| Q3 25 | 2.8% | 0.5% | ||
| Q2 25 | 6.1% | 0.7% | ||
| Q1 25 | 6.3% | 0.9% | ||
| Q4 24 | 6.7% | 5.5% | ||
| Q3 24 | 7.2% | 1.4% | ||
| Q2 24 | 3.3% | 1.0% |
现金转化率AMPHWSFS
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 3.03× | ||
| Q3 25 | 3.03× | 1.59× | ||
| Q2 25 | 1.15× | 0.51× | ||
| Q1 25 | 1.39× | 0.13× | ||
| Q4 24 | 0.76× | 3.43× | ||
| Q3 24 | 1.48× | 0.05× | ||
| Q2 24 | 1.82× | 0.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
WSFS
暂无分部数据
